logo-loader
viewBod Australia Ltd

Bod Australia secures first medicinal cannabis prescription, enters research collaboration

The company is well-positioned to benefit from the ongoing sale of its cannabis oils to patients through approved prescribers.

1540438696_shutterstock_734579047.jpg
Bod is an integrated cannabis business developing over-the-counter and prescription products

Bod Australia Ltd (ASX:BDA) has secured the first approved prescription for its medicinal cannabis product MediCabilis with a patient through Cannabis Access Clinics, owned and operated by Biologics Research Institute Australia (BRIA).

Bod has also entered into a research collaboration agreement with Biologics to study the effects of MediCabilis on a broad range of patient outcomes.

The agreement will result in Bod’s sublingual cannabis wafer being available to patients in Cannabis Access’ networks once Bod completes the product’s phase I clinical trial.

Bod expects to benefit from additional sales of cannabis oil in the near-term and the agreement provides the company with access to Cannabis Access Clinics’ patient pool as well as feedback on MediCabilis’ efficacy as a treatment.

‘Large pool of potential patients’

Bod chief executive officer Jo Patterson said the agreement was very beneficial for Bod.

She said: “It has not only resulted in the company receiving its first prescription for MediCabilis, but also provides us with a large pool of potential patients and prescribers from the Cannabis Access Clinics network that will provide independent and ongoing feedback around our medicinal cannabis product offering.

“Cannabis Access Clinics has the most extensive network of doctors and patients in Australia and New Zealand and are a first mover in navigating the regulatory pathway for prescribing and monitoring medicinal cannabis therapies.

“We look forward to working with them and their network of physicians, patients and academics to continue our commitment to better educate the public around the benefits of medicinal cannabis.”

READ: Bod Australia crosses a major milestone in developing cannabis wafer

Bod will gain access to Cannabis Access’ extensive patient treatment and monitoring platform across Australia and New Zealand.

The MediCabilis trial will provide feedback on the product’s ability to treat symptoms including anxiety, pain, post-chemotherapy nausea and vomiting, and epilepsy.

The data from the study will assist in refining phase II clinical trial parameters which will test specific indications of the product.

Cannabis Access Clinics medical director Dr Sanjay Nijhawan said:

“We place strong emphasis on ensuring medicinal cannabis is an appropriate treatment for our patients and undertake meticulous monitoring and data collection on an ongoing basis.

“We are pleased to offer our network of clinics as a research platform to help advance our understanding of how cannabis therapies work for particular patient groups.”

Quick facts: Bod Australia Ltd

Price: 0.23 AUD

ASX:BDA
Market: ASX
Market Cap: $21.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Matador Mining Ltd nearing release of scoping study for Cape Ray gold project

  Matador Mining Ltd's (ASX:MZZ) executive director Adam Kiley tells Proactive's Andrew Scott they're getting to close to announcing a scoping study for its Cape Ray Gold Project in Newfoundland, Canada, which is expected to be released 'later this quarter'. ''Also in the past quarter...

17 hours, 1 minute ago

3 min read